You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Biomarkers in NSCLC: From Detection to Novel Therapeutics and Decision-Making

  • Authors: Joshua Sabari, MD; Heather Wakelee, MD, FASCO
  • CME / ABIM MOC / CE Released: 6/29/2023
  • Valid for credit through: 6/29/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pathologists, pulmonologists, and pharmacists.

The goal of this activity is for learners to be better able to recognize the impact of the latest clinical evidence on the comprehensive care of patients with molecularly altered NSCLC.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Biomarker heterogeneity of NSCLC
    • Latest clinical trial data evaluating therapies for patients with molecularly-altered NSCLC
  • Have greater competence related to
    • Identifying patients who are eligible for therapies for molecularly-altered NSCLC
  • Demonstrate greater confidence in their ability to
    • Integrate evolving evidence into the comprehensive care of patients with molecularly-altered NSCLC


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Joshua Sabari, MD

    Assistant Professor of Medicine  
    NYU Grossman School of Medicine  
    Thoracic Medical Oncologist  
    NYU Langone Health
    Perlmutter Cancer Center  
    New York, New York


    Joshua Sabari, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; AstraZeneca; Genentech, Inc.; Janssen Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics; Navire; Novocure; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Takeda Pharmaceuticals North America, Inc.
    Research funding from: AstraZeneca; Janssen Pharmaceuticals; Mirati Therapeutics; Regeneron Pharmaceuticals, Inc.

  • Heather Wakelee, MD, FASCO

    Professor of Medicine  
    Chief, Division of Oncology  
    Stanford University School of Medicine  
    Deputy Director  
    Stanford Cancer Institute  
    Stanford, California 


    Heather Wakelee, MD, FASCO, has the following relevant financial relationships:
    Consultant or advisor for: Genentech/Roche; Merck & Co., Inc.; Mirati Therapeutics (former)
    Research funding from: AstraZeneca; Bayer HealthCare; Bristol-Myers Squibb Company; Clovis Oncology; Genentech/Roche; Helsinn Therapeutics, Inc; Merck & Co., Inc.; Seagen Inc.; Xcovery


  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC


    Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-23-272-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Biomarkers in NSCLC: From Detection to Novel Therapeutics and Decision-Making

Authors: Joshua Sabari, MD; Heather Wakelee, MD, FASCOFaculty and Disclosures

CME / ABIM MOC / CE Released: 6/29/2023

Valid for credit through: 6/29/2024, 11:59 PM EST


A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print